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PURPOSE. To assess in vitro cytotoxic activity and antiangiogenic effect, ocular and systemic
disposition, and toxicity of digoxin in rabbits after intravitreal injection as a potential
candidate for retinoblastoma treatment.
METHODS. A panel of two retinoblastoma and three endothelial cell types were exposed to
increasing concentrations of digoxin in a conventional (72-hour exposure) and metronomic
(daily exposure) treatment scheme. Cytotoxicity was defined as the digoxin concentration
that killed 50% of the cells (IC50) and was assessed with a vital dye in all cell types. Induction
of apoptosis and cell-cycle status were evaluated by flow cytometry after both treatment
schemes. Ocular and systemic disposition after intravitreal injection as well as toxicity was
assessed in rabbits. Electroretinograms (ERGs) were recorded before and after digoxin doses
and histopathological examinations were performed after enucleation.
RESULTS. Digoxin was cytotoxic to retinoblastoma and endothelial cells under conventional
and metronomic treatment. IC50 was comparable between both schedules and induced
apoptosis in all cell lines. Calculated vitreous digoxin Cmax was 8.5 lg/mL and the levels
remained above the IC50 for at least 24 hours after intravitreal injection. Plasma digoxin
concentration was below 0.5 ng/ml. Retinal toxicity was evident after the third intravitreal
dose with considerable changes in the ERG and histologic damage to the retina.
CONCLUSIONS. Digoxin has antitumor activity for retinoblastoma while exerting antiangiogenic
activity in vitro at similar concentrations. Metronomic treatment showed no advantage in
terms of dose for cytotoxic effect. Four biweekly injections of digoxin led to local toxicity to
the retina but no systemic toxicity in rabbits.
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Despite recent advances in the local routes for chemother-apy delivery, few agents have been incorporated in the
chemotherapy armamentarium for retinoblastoma treat-
ment.1–3 Vitreous seeding of the tumor remains the more
important obstacle to cure. Intravitreal injection of chemother-
apeutic drugs became a critical tool for the successful
treatment of vitreous seeds.2,3 Melphalan is the most commonly
used chemotherapy agent for intravitreal injection, but its
retinal toxicity is dose-limiting and new agents for intravitreal
use that could act by a different mechanism are needed.4 Using
a high-throughput screening approach, Antczak et al.5 identi-
fied cardenolides as active antiproliferative agents in human cell
lines of ocular tumors and xenograft models of retinoblastoma.
The in vitro antiproliferative activity of the cardenolides
exceeded all of the currently available chemotherapeutic agents
presently being used to treat retinoblastoma.
Among the cardenolides, digoxin is a positive inotropic
agent used for congestive heart failure and atrial fibrillation.
Several reports have shown in vitro cytotoxic effects in
different cell lines as well as in adult cancer patients
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concomitantly treated with cardenolides (reviewed in Ref. 6).
Many mechanisms have been proposed to explain the
antitumor effect.6–9 Cardiac glycosides (and derivatives) were
evaluated clinically in phase I studies in patients with breast
cancer10 but not yet in studies in pediatric patients with
cancer.
The preferred route of digoxin administration in children
with retinoblastoma would depend not only on its ability to
reach the target tissues but also on possible systemic toxicity.
Super-selective ophthalmic artery infusion (SSOAI) was used in
one retinoblastoma patient with a measurable but not
sustained clinical response.11 Although SSOAI led to 6-fold
higher exposure in the vitreous compared with periocular
injection of the same dose of topotecan in a swine model, the
penetration of the drug into the vitreous depends on the
physicochemical properties of the drug.12 Therefore, this may
not be the preferred route for digoxin administration in
retinoblastoma treatment. Additionally, digoxin has a narrow
therapeutic range and well-known consequent cardiovascular
toxicity,13 favoring intravitreous delivery because this route
allows a 50-times higher exposure in the vitreous compared
with the plasma of rabbits.14 In addition, since intravitreally
implanted devices may be designed to achieve a sustained drug
release that would be of interest for retinoblastoma, based on
the antiangiogenic activity of cardenolides and that vessel
density was previously related to the extent of tissue invasion
in patients with retinoblastoma, we decided to evaluate the
activity of digoxin as an antiangiogenic agent as an alternative
strategy for inhibiting retinoblastoma.15–17 Metronomic deliv-
ery of chemotherapy is effective both in vitro and in vivo in
different pediatric solid tumors.18–21 This treatment modality
refers to the frequent and repetitive administration of the
chemotherapeutic agent at relatively low doses compared with
conventional chemotherapy without prolonged drug-free
breaks between cycles.22–24 The main advantage involves
avoiding acute severe adverse events because of the lower
maximum plasma concentration and systemic exposure after
each dose, while obtaining the same clinical outcome as after
the maximum tolerated dose.22 Metronomic scheme targets
not only tumor-associated vascular development but also has a
direct cytotoxic effect on tumor cells and exerts some activity
in the immune mechanisms for tumor control.22,23 In this
study, we undertook a multimodal approach in order to
evaluate in vitro and in vivo efficacy and safety of intravitreal
digoxin as a potential candidate for retinoblastoma treatment
based on:
1. In vitro cytotoxicity studies of digoxin to determine the
inhibitory concentrations in two retinoblastoma cell
lines;
2. In vitro cytotoxicity studies in three endothelial cell
lines to assess the antiangiogenic effect of digoxin;
3. Comparison of the in vitro cytotoxic effect of digoxin in
retinoblastoma and endothelial cells under two sched-
ules, conventional and metronomic treatment;
4. In vivo pharmacokinetic characterization of digoxin in
the vitreous and ocular tissues and plasma of rabbits
after an intravitreal dose; and
5. Safety studies in rabbits after repetitive intravitreal
doses.
METHODS
Cell Culture
Y79 and WERI-RB1 cells were obtained from the American Type
Culture Collection (Manassas, VA, USA). Cells were maintained
in RPMI 1640 culture media (Invitrogen-Life Technologies,
Rockville, MD, USA) with various supplements as previously
described.25 Human umbilical vein endothelial cells (HUVEC)
and late outgrowth endothelial progenitor cells (EPC) were
obtained from umbilical cord vein and blood, respectively, after
full-term deliveries.26 The institutional review board of the
National Academy of Medicine, Argentina approved the protocol
and informed consent was obtained from the mothers before
collecting the cord blood. Human microvascular endothelial
cells (HMEC-1) were obtained from the American Type Culture
Collection. All endothelial cells were maintained in endothelial
growth medium-2 (EGM2) from Lonza (Walkersville, MD, USA)
with supplements as previously described.24
Conventional and Metronomic Dosing of Digoxin
Retinoblastoma and endothelial cell lines were incubated with
digoxin for 72 hours using conventional treatment as well as
low doses for longer periods of time (between 5 and 7 days)
referred to as metronomic treatment.
To assess the effect of conventional dosing of digoxin,
retinoblastoma cell lines (Y79 and WERI-RB1) were seeded in
96-well plates and allowed to grow for 24 hours. Subsequently,
cells were exposed to eight different concentrations of digoxin
(0.01–100 lM) for 72 hours. Five independent assays were
performed in triplicates for each concentration of digoxin.
Digoxin IC50 was determined for each assay and thereafter the
median (range) was calculated. For metronomic dosing of
digoxin, cells were exposed to digoxin in a dose range as
indicated (0.001–10 lM) on the first day of treatment. Every 24
hours, cells were centrifuged for 10 minutes, the medium was
removed, and subsequently fresh digoxin solution with new
medium was added and cells were resuspended. This process
was carried out continuously up to 168 hours (7 days).
Human umbilical vein endothelial cells, HMEC, and EPC
were seeded into 96-well tissue culture plates at 2 3 104 cells
and grown under standard culture conditions. Cells were
treated with either a single conventional dose (MTD) or daily
digoxin (metronomic therapy) for 120 hours with eight
different concentrations of digoxin (0.001–50 lM) adding
fresh digoxin solution with new medium as previously
described for retinoblastoma cell lines.
In all cases, wells with medium and PBS served as controls.
Growth Inhibition Assessment
After MTD and metronomic treatment, cell viability of Y79 and
WERI-RB1 was assessed by adding 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich Corp., St.
Louis, MO, USA). Viable endothelial cells after MTD or
metronomic treatment were counted by measuring acid
phosphatase activity after incubation with the chromogenic
substrate pNPP for 1 hour at 378C. Thereafter, the reaction was
stopped with NaOH (1 N) and the reaction product p-nitro-
phenol was measured at 405 nm using a spectrophotometer.
Both techniques of cell viability assessment led to comparable
IC50s in preliminary studies carried out in retinoblastoma and
endothelial cells. In those studies the mean (SD) digoxin IC50 in
Y79 determined using MTT and pNPP was 0.114 (0.015) and
0.116 lM (0.010), respectively, and 0.016 (0.005) and 0.013 lM
(0.003) for EPC (P > 0.05). The IC50 was defined as the
concentration of the chemotherapy agent that killed 50% of the
cells (or the concentration that allows a 50% cell survival).
Cell Cycle and Apoptosis Assay
Apoptosis analysis was performed by flow cytometry using the
Annexin V-FITC Apoptosis Detection Kit II (BD Pharmingen,
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San Diego, CA, USA). Briefly, 25 3 103 retinoblastoma and
endothelial cells were seeded in 24-well plates and treated with
digoxin at the IC50 in a conventional or metronomic fashion.
Afterward, cells were washed and incubated for 15 minutes
with FITC-annexin V in binding buffer at 378C. Then, cells
were resuspended in propidium iodide solution and immedi-
ately analyzed by flow cytometry using FACSCalibur (BD
Biosciences, San Jose, CA, USA). Cell viability and morphologic
changes were also assessed by a second method under the
fluorescence microscope by labeling with acridine orange (100
lg/mL)/propidium iodide (100 lg/mL; Sigma-Aldrich Corp.)
double-staining after digoxin treatment.
Cell-cycle distribution was assessed at the calculated IC50
of digoxin for each cell line after conventional and metronomic
treatment using growth inhibition tests. Briefly, cells were
synchronized overnight in culture medium with 1% fetal calf
serum before the simultaneous expression of the cell
proliferation-associated nuclear antigen Ki67 and DNA content
(PI) was determined by flow cytometry. Cells were harvested
and fixed in 70% (vol/vol) ethanol and incubated at 208C
overnight. Then, cells were washed and resuspended in PBS
0.5% Nonidet P40 containing RNase A (75 UI/mL, Sigma-
Aldrich Corp.) for 30 minutes at 378C. Cells were immuno-
stained using FITC-labeled anti-Ki67 (BD Transduction Labora-
tories, San Jose, CA, USA) for 45 minutes. Finally, cells were
washed and stained with propidium iodide (0.5 lg/mL) and
immediately analyzed by flow cytometry. Quadrant markers
were set using a negative isotypic control and each phase of
the cell cycle was calculated using FlowJo (Tree Star, Inc.,
Ashland, OR, USA) analysis software. This assay was also used
to assess the degree of apoptosis under each treatment by
quantifying the cells arrested in sub-G1.
Pharmacokinetic Study of Digoxin After
Intravitreal Dose
A total of 17 New Zealand rabbits weighing between 1.8 and
2.2 kg were used for ocular and systemic pharmacokinetic
characterization of digoxin after intravitreal injection of one
eye. The fellow eye was used as a control. All experiments
carried out in rabbits adhered to the tenets of the Institutional
Committee for Animal Care of the Garrahan Hospital and the
ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. In all cases, the animals were fed standard
laboratory food and allowed free access to water and housed
under 12-hour light–dark cycles.
Sample Collection and Analytical Assay. Under general
anesthesia, the animals received a single intravitreal injection
of 10 lg digoxin (0.1 mL) prepared by serial dilutions in 0.9%
saline of the commercial drug product (Digoxina, Larjan,
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina) in
a safety cabinet.
The selection of the dose was based on the amount of
digoxin that after injection could result in pharmacologically
active levels in the vitreous of a rabbit (1.5 ml27) for at least 4
hours after injection but also, that resulted in a low systemic
exposure as a surrogate of cardiac toxicity for its direct
consequence in the translation to the clinics that was the
ultimate goal of these studies. Thus, the dose was established
by the threshold of biological activity or IC50 and we chose
that obtained by Antczak et al.5 that was 10-fold higher than
the value obtained in the present study. Thus, we worked with
the highest dose to study if pharmacologically active levels
were attained in the vitreous of the animal, the interval of time
above the threshold, and if this high dose led to any measurable
systemic exposure because of the concern of systemic toxicity
in the clinical setting.
Only one vitreous sample (100 lL) was obtained per eye in
the anesthetized animal by aspiration from the inner region of
the posterior eye chamber with an 18-G needle at: 0.083, 0.25,
1, 2, 4, 6, 8, 16, 24, and 48 hours after digoxin injection.
Vitreous samples were collected and treated as previously
described.14 In addition, venous blood samples (200 lL) were
collected from the ear vein in sodium heparinized tubes before
injection and at: 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 16, 24, and 48
hours after intravitreal digoxin administration.28 Up to two
blood samples were collected from each animal except for
those whose eyes were sampled at short times (0.083 and 0.25
hours), from whom only one blood sample was collected. The
samples were immediately centrifuged and plasma was
separated for digoxin assay. Finally, the animals were eutha-
nized using an overdose of intravenous sodium pentobarbital
(80 mg/kg body weight) and both eyes were immediately
enucleated. The retinal tissue was dissected from both the
control and treated eyes, treated as previously reported,25 and
tissue extracts were stored at 208C until assay.
Vitreous and retinal samples were quantified for digoxin by
HPLC coupled with an UV detector set at 220 nm after
validating a modified method reported by others.29,30 The
linear ranges for vitreous and retina assays ranged from 0.1 to
15 lg/mL and 0.05 to 1.0 lg/mL, respectively. Interday
precision was less than 6.8% for both assays. Heart and kidneys
from the euthanized animals were washed in cold PBS,
weighed, and homogenized with methanolic acid solution in
a 1-to-5 dilution using IKA T25 Ultra-Turrax (Staufen,
Germany). After centrifugation, methanolic supernatants were
stored at 208C until HPLC assay.
Lastly, concentration of digoxin in plasma samples was
measured by microparticle enzyme immunoassay (MEIA) on
the AxSYM analyzer (Abbott Laboratories, Abbott Park, IL,
USA). Previously, three calibration curves were performed in
plasma from normal and nontreated rabbits, supplemented
with external digoxin standard solutions to assess the matrix
effects when using plasma from animals.
Pharmacokinetic Analysis. A two- and a one-compart-
ment model was fit to the vitreous and plasma digoxin
concentration versus time data, respectively, for all animals
using the maximum likelihood estimation method as imple-
mented in ADAPT II (Biomedical Simulations Resource, Los
Angeles, CA, USA).31 Model parameters that were estimated
include the intercompartmental rate constants of transfer of
digoxin from the vitreous compartment to the rest of the body
(Kvc) and back to the vitreous (Kcv), and the apparent
volumes of distribution in the vitreous and the body.14
FIGURE 1. Representative micrograph of a retinal section after a single
dose of digoxin (dose, 10 lg).
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In Vivo Safety Study After Intravitreal Digoxin
A preliminary toxicity examination was performed in two
animals in order to assess general outcome after a single
intravitreal dose of digoxin corresponding to the dose used in
the pharmacokinetic study. One week after a single 10-lg dose
to the right eye of two rabbits, retinal damage with cystic
degenerative changes and complete loss of a- and b-wave
amplitude and implicit time were observed compared with the
parameters before injection (Fig. 1). Assuming that digoxin
follows linear pharmacokinetics after intravitreal injection, we
simulated the vitreous concentration data after administering a
dose of 1 lg based on the pharmacokinetic parameters obtained
in the rabbits. The predicted vitreous concentrations were
higher than the IC50 obtained in WERI-RB for approximately 7
hours. Therefore, this dose was expected to lead to pharmaco-
logically active levels in the vitreous with potential translation
into the clinics and thus, was used to evaluate the ocular toxicity
after four intravitreal injections of digoxin administered every 2
weeks. Serial dilution of commercial digoxin with sterile saline
was performed in order to obtain a final concentration of 10 lg/
ml. Based on our previous reports in which we showed that the
technique of intravitreal injection did not lead to ocular toxicity,
each digoxin-treated animal was its own control using the
contralateral eye treated with the diluted vehicle.28
Before intravitreal injections and electrophysiological re-
cordings, pupillary mydriasis and corneal topical anesthesia
were induced as described elsewhere.4,28 No anterior chamber
paracentesis was performed. Then, the right eye was opened
with an eyelid retractor and 0.1 mL of the digoxin solution was
injected using a 33-G needle attached to a tuberculin syringe.
To study the potential toxic effects of the commercial vehicle
in which digoxin was dissolved, the vehicle was prepared
following the composition described by the manufacturer,
diluted with sterile saline, filtered through a 0.22-lm filter, and
0.1 mL was injected in the contralateral eye in the same
session. This procedure was performed every 2 weeks with a
total of four administrations to each eye. After finishing the
experiments the rabbits were euthanized as previously
described and the eyes were immediately enucleated.
Systemic and Ocular Toxicity Evaluation. All animals
were evaluated for potential signs of systemic toxicity on a
weekly basis. Temporal variation of body weight, hair loss, and
routine hematology tests including hematocrit, platelet count,
red blood cell count, neutrophils (% of total white blood cells),
and hemoglobin level were recorded in the study period. A
baseline indirect ophthalmoscopic examination was done and
repeated before each digoxin or vehicle injection. Under
general anesthesia (ketamine hydrochloride, 37.5 mg/kg, IM
and xylazine 5 mg/kg, intramuscular) electrophysiological
recordings (ERG) were performed in both eyes of the animals
before all four intravitreal injections and 2 weeks after the last
dose. Mixed rod–cone ERGs were obtained on each occasion
using the technique described in our previous studies.4,28
Finally, fundus photography and fluorescein angiography (FA)
were done after the fourth dose of digoxin and 1 week before
enucleation.
Histopathology. Two weeks after the fourth dose of
digoxin, the rabbits were euthanatized and immediately
enucleated. The vitreous was separated and stored at 208C
for digoxin assay. Eyes were immersed in 4% paraformaldehyde
in 0.1 M of phosphate buffer (pH 7.4) overnight and processed
for routine histopathological examination.
Statistical Analysis
The cell survival curves for retinoblastoma and endothelial
cells were presented as the percentage of surviving cells versus
digoxin concentration. The IC50 values were calculated by
nonlinear regression analysis using GraphPad Prism (GraphPad
Software, Inc., La Jolla, CA, USA). t-test analysis was performed
to compare the IC50s obtained using conventional and
metronomic treatment with digoxin on each cell line. The
Mann-Whitney U test was used to test for differences in ERG
parameters between digoxin- and vehicle-treated eyes at
different times after starting the study. We also assessed the
effect of repeated intravitreal injections of digoxin on
hematological parameters and body weight by means of a
repeated measure ANOVA with Bonferroni test a posteriori. In
all cases, the significance level was set at 0.05.
RESULTS
Effect of Conventional and Metronomic Digoxin
Treatment on Cultured Retinoblastoma Cells
We observed strong cytotoxic activity against both retinoblas-
toma cell lines with calculated IC50s ranging from 0.10 to 0.19
lM (Table 1). Using a protracted treatment schedule of daily
digoxin administration to retinoblastoma cells, we observed a
growth inhibitory effect comparable to the cytotoxic effect
obtained by a single-day treatment (Figs. 2A–D). No significant
statistical difference was detected in the IC50s of both cell
lines when comparing conventional with metronomic treat-
ment (P > 0.05, Table 1).
Endothelial Cell Sensitivity to Conventional and
Metronomic Digoxin
A strong and concentration-dependent antiproliferative effect
was observed when HUVEC and EPC endothelial cells were
exposed to conventional and single doses of digoxin (Figs. 2E,
2F, not shown for HMEC). As shown in Table 1, the mean (SD)
calculated IC50s were 0.016 (0.001), 0.019 (0.002), and 0.021
(0.011) lM for HUVEC, HMEC, and EPC, respectively. When
these cells were treated using a metronomic schedule with
continuous exposure to digoxin over 120 hours, there was no
difference in cell viability compared with the IC50s obtained
under conventional treatment (P > 0.05, Table 1; Figs. 2G, 2H).
In addition, HUVEC was the most sensitive endothelial cell
type with an IC50 of 0.016 lM after conventional treatment.
Apoptosis Induced by Digoxin in Retinoblastoma
and Endothelial Cells
As shown in Figure 3A, the percentage of Y79 cells that
underwent necrosis (Annexin-V-/PIþ) after conventional treat-
ment was higher than that obtained after metronomic
treatment. However, no differences in the percentage of
necrotic cells were observed between treatment schemes in
TABLE 1. Cytotoxic Activity of Digoxin on Retinoblastoma and
Endothelial Cells After Conventional and Metronomic Treatment
Cell Line
Conventional
IC50, lM
Metronomic
IC50, lM
Y79 0.100 (0.027) 0.101 (0.040)
WERI-RB1 0.191 (0.063) 0.130 (0.034)
HUVEC 0.016 (0.001) 0.017 (0.001)
EPC 0.021 (0.011) 0.019 (0.002)
HMEC 0.019 (0.002) 0.013*
Data are shown as means (SD).
* Only one replicate was available for HMEC with metronomic
digoxin treatment.
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FIGURE 2. Effect of digoxin on retinoblastoma and endothelial cell proliferation in a conventional and a metronomic treatment scheme. (A, B)
Growth inhibition assay performed on Y79 and WERI-RB1 cell lines, respectively, using MTT after 72-hour incubation of a conventional regimen and
(C, D) metronomic treatment for 7 days with different digoxin concentrations; (E, F) growth inhibition assessment of HUVEC and EPC cell lines,
respectively after conventional and (G, H) metronomic digoxin treatment. Symbols represent percentage of cell proliferation as compared with
untreated control cells, expressed as means (SEM) of three independent experiments, each performed in triplicates.
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endothelial cells. After both treatment schemes at digoxin IC50
the percentage range of apoptosis was 37% to 58%.
These results were confirmed using acridine orange/
propidium as a second technique. Using both conventional
and metronomic schemes, cells exhibited chromatin conden-
sation, shown as bright green fluorescence, and a reduction of
cell size and nuclear fragmentation (Fig. 3B). Late-stage
apoptosis induced by digoxin was identified by the reddish-
orange color obtained by propidium iodide binding to
denatured DNA. The same morphologic changes were
observed in the three endothelial cell types (data not shown).
Altogether, our results demonstrate that the proportion of
apoptotic cells remained constant between treatment schemes
in all cell lines except in retinoblastoma cells, which mostly
suffered necrotic events.
Digoxin Induces G0 Cell Cycle Arrest
To examine the effects of digoxin on the cell cycle, we studied
cell cycle progression in the Y79 retinoblastoma cell line and
endothelial HUVEC, HMEC, and EPC cell types by flow
cytometry using ki-67 and PI double-staining. We observed
that at concentrations of digoxin effective to reduce the
retinoblastoma and endothelial cell number by 50% upon
either conventional (Fig. 3C) or metronomic (Fig. 3D)
treatment, impaired cell-cycle progression induced cells to
accumulate in G0. The increase in the G0-phase cell
population was accompanied by a concomitant reduction of
cells in the G1 phase. This arrest in G0 was more evident in the
retinoblastoma Y79 cell line with an increase from 26% of the
control-cell fraction to 61% in the digoxin treated-cell fraction
after conventional treatment. The increase in G0 was
accompanied by a subsequent decrease of the cell fraction in
G1 from 51% (control cells) to 13% (digoxin-treated cells) with
similar fractions at G2/M. Results after the metronomic scheme
at the IC50 were even more evident in Y79 cells, showing an
increase at G0 from 9% of the control-cell fraction to 70% of the
digoxin-treated cell fraction. Again, the observed increase at
G0 was related to a subsequent decrease of the cell fraction in
G1 from 75% (control cells) to 9% (digoxin-treated cells).
FIGURE 3. Effect of digoxin on the apoptosis and cell cycle of retinoblastoma and endothelial cells after conventional and metronomic treatment.
(A) Apoptosis was examined using annexin V-FITC/PI staining. Percentages of viable (dotted bars), early apoptotic (right dashed bars), and late
apoptotic (white bars)/necrotic cells (black bars) are shown after conventional (72 hours) and metronomic (7 days) digoxin treatment. (B)
Morphologic changes of Y79 cells treated with digoxin after one dose at the IC50 (upper row, conventional) or continuous treatment (lower row,
metronomic) observed by fluorescent microscope (magnification:3200). Untreated Y79 cells demonstrated a normal structure without prominent
apoptosis after conventional or metronomic treatment (stained green with acridine orange). Y79 cells after conventional or metronomic exposure
to the IC50 of digoxin (middle picture), with clear hallmarks of late apoptosis are shown in orange using propidium iodide. (C) Effect of
conventional and (D) metronomic digoxin exposure on cell cycle distribution of retinoblastoma and endothelial cells. Dotted bars, percentage of
cells in G0; white bars, percentage of cells in G1; black bars, percentage of cells in G2/M. Digoxin induced a cell cycle arrest at G0 phase after
treatment at the IC50 despite the treatment fashion and cell line.
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Furthermore, a similar effect was seen in HUVEC in which a
cell arrest in G0 increased from 17% to 50% after conventional
treatment at the expense of a reduction in G1 from 64% to
40%. Similar changes in the percentage of cells at the different
phases of the cell cycle were observed after the metronomic
treatment of HUVEC. Finally, conventional and metronomic
treatment of EPC and HMEC with digoxin led to similar but
more modest cell-cycle arrests as previously described for
HUVECs and Y79 cells. The number of cells in the G2/M
phases of the cell cycle showed no changes when comparing
digoxin-treated cells with the controls of the different cell
lines.
Digoxin Pharmacokinetics After Intravitreal
Injection
The disposition of digoxin after a single dose of 10 lg into the
vitreous humor of rabbits was well described by a two-
compartment model as shown in Figure 4A. A total of 17
vitreous samples were obtained at different time points. Three
animals were reported to the Local Committee and were not
included in the present study due to an infection in the eye
that required treatment with antibiotics, hematologic disorder
confirmed in the routine testing, and the third animal died
during anesthesia. The maximum vitreous concentration
(Cmax) was 8.5 lg/mL attained 5 minutes after the intravitreal
injection. Digoxin was not detected in the retina or vitreous of
the contralateral eye at any time post injection.
Our results showed that after a single intravitreal dose of 10
lg, plasma levels (n ¼ 25) were below 0.5 ng/mL at all times
after the injection except for one animal that showed a
concentration of 0.7 ng/mL 30 minutes after intravitreal
injection (Fig. 4B). Interestingly, the digoxin area under the
plasma concentration versus time calculated up to 48 hours
after the administration (AUCpl) was 12.6 ng 3 h/mL,
corresponding to 0.04% of the AUC reached in the vitreous
compartment (AUCvit, 33.2 lg 3 h/mL).
Retinal digoxin concentrations (n ¼ 17) versus time are
depicted in Figure 4C. The maximum retinal concentration
predicted by the model was 8.5 lg/g of tissue attained 15
minutes after administration. In addition, retinal concentra-
tions were quantifiable up to 16 hours. Pharmacokinetic
parameters after a single intravitreal injection of digoxin are
reported in Table 2.
Finally, kidney and heart samples from the animals were
nonquantifiable for digoxin at all times after intravitreal
injection.
Ocular and Systemic Toxicity After Multiple
Intravitreal Digoxin
Animals treated with four doses of intravitreal digoxin showed
no significant changes in body weight and hematocrit, platelet,
red blood cell, or neutrophil counts (compared with percent of
total white blood cells), or hemoglobin content during the
study period (P > 0.05).
Serum digoxin was nondetectable 2 weeks after each
intravitreal injection (prior to the next dose).
Eyes treated with digoxin or the diluted vehicle did not
show any evidence of inflammation during the follow-up
period. The cornea, anterior chamber, and vitreous remained
clear in all but two eyes. In these eyes cataracts developed after
the second and third injection with diluted vehicle, respec-
tively. No fundus changes attributable to drug toxicity were
evident in vehicle-treated eyes but two eyes of the digoxin-
treated group showed a hypopigmented focal area in the
inferior retina corresponding to retinal atrophy and choroidal
hypovascularity. Lastly, Figures 5A and 5B depict the digoxin-
treated eye of a representative animal 2 weeks after the fourth
injection. Fundoscopy and FA showed no decrease in the
number or changes in the quality of retinal vessels.
Electrophysiological Studies
We found no significant changes in a-wave and b-wave implicit
times when comparing digoxin- to vehicle-treated eyes or
digoxin-treated eyes before any injection and at different times
during the study period (P > 0.05). However, a significant
reduction in b-wave and a-wave amplitude was observed in the
digoxin-treated eyes at least 2 weeks after the second
intravitreal injection compared with the parameter obtained
in the same eye before starting treatment as shown in Table 3
FIGURE 4. Ocular digoxin pharmacokinetics after a single intravitreal injection. Digoxin concentration versus time profile in (A) vitreous, (B)
plasma, and (C) retina of treated eyes after a single intravitreal injection of 10 lg digoxin. Full symbols represent individual data points for vitreous
and plasma concentrations, the solid lines show the predicted concentrations. The dotted and dashed lines (A) represent digoxin IC50 obtained in
Y79 and WERI-RB1, respectively.
TABLE 2. Pharmacokinetic Parameters of Digoxin After a Single-Dose
Intravitreal Injection in Rabbits
Pharmaco-
kinetic
Parameter
Vitreous Humor
(Injected Eye) Plasma
Retina*
(Injected Eye)
Cmax† 8.5 lg/ml 0.0004 lg/ml 8.5 lg/g
AUC 33.2 lg 3 h/ml 0.0126 lg 3 h/ml 42.4 lg 3 h/g
* Data is expressed per gram of tissue.
† Mean (SE) estimates of Cmax calculated with the pharmacokinetic
model.
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(P < 0.05). Two weeks after the third dose of digoxin, the a-
and b-wave amplitude declined significantly in the digoxin-
compared with the vehicle-treated eyes as depicted for a
representative animal in Figure 5C (P < 0.05). No recovery in
a- or b-wave amplitude could be recorded after 2 weeks of the
full treatment schedule (four doses injected every 2 weeks) and
before enucleation (P < 0.05). No statistical difference was
found in a-wave or b-wave amplitude in vehicle-treated eyes
throughout the entire follow-up period.
Thus, the present data shown in Table 3 confirm that
biweekly intravitreal digoxin injections of 1 lg induced retinal
toxicity according to the ERG responses after the third
injection.
Histologic Analysis
Light microscopy of retinal sections of vehicle- and digoxin-
treated eyes revealed that the diluted vehicle induced no toxic
effects in the peripheral, equatorial, and posterior retina (Figs.
6A, 6C, 6E). However, we found histologic evidence of focal
outer retinal atrophy in digoxin-treated eyes. The outer nuclear
layers of the retina and the photoreceptor structures were
severely impaired but the damage was constricted to the
equatorial area (Fig. 6D). Those areas where the integrity of the
outer retina was lost were in continuity with intact retina from
the peripheral (Fig. 6B) and posterior retina (Fig. 6F).
Medullated nerve fibers showed normal appearance in both
vehicle and digoxin-treated eyes (Figs. 6G, 6H, respectively).
Lastly, the optic discs of vehicle and digoxin-treated eyes
showed no evidence of vascular alterations and myelin sheaths
remained unaltered as well as those eyes from treated with the
vehicle (Figs. 6H, 6J, respectively).
DISCUSSION
We confirm previous results from high-throughput screening
analysis showing that digoxin exerts a potent cytotoxic effect
on retinoblastoma cell lines with an IC50 between 0.10 and
0.19 lM. The potential discrepancies between the present
results and the original high-throughput screening study that
showed higher IC50s for digoxin in WERI-RB1 and Y79 cell
lines may be attributable to different incubation times for drug
exposure to the cells and the density of cells per well used for
the cytotoxicity studies.5,32
Current treatment of eyes with vitreous seeds includes
multiple intravitreal injections of melphalan.33 This treatment
has led to the ocular survival of eyes that could not be saved in
FIGURE 5. (A) Representative color fundus and (B) fluorescein angiography of a digoxin-treated eye showing normal vessels. (C) Representative
electroretinogram response with time after multiple intravitreal injections of digoxin in a rabbit eye (top, digoxin-treated eye with four biweekly
injections of 1 l digoxin; bottom, vehicle-treated eye).
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the past with other routes for drug delivery using classical
antineoplastic agents. On the other hand, we previously
reported the toxicity to the retina and the decline in vision
with time of treatment/number of injections of melphalan.4
Moreover, despite the attained improvement, we still face with
eyes that relapse to intravitreal melphalan.33 Specifically, for
these eyes, nowadays there are no alternative agents active
against retinoblastoma and most patients undergo enucleation.
Therefore, digoxin may be an options based on its potent
cytotoxic activity against retinoblastoma cell lines.
Consistent with previous reports we found that, at
concentrations effective in reducing the retinoblastoma cells
by 50%, digoxin exhibited proapoptotic activity.5,8 Complex
pathways have previously been reported to trigger apoptosis
after cardenolide treatment of different cell lines including
changes in intracellular ion homeostasis due to the inhibition
of Naþ/KþATPase.6,8 However, further studies are necessary to
assess the mechanism of digoxin-induced growth arrest in
retinoblastoma cells.
Digoxin may also exert its antitumor effect in retinoblasto-
ma by targeting the endothelium leading to antiangiogenic
effects. The role of tumor angiogenesis in retinoblastoma
growth is well documented.34,35 Therefore, we chose three
types of endothelial cells, HUVEC, EPC, and HMEC, to evaluate
digoxin-induced antiangiogenesis. Human umbilical vein endo-
thelial cells are popular cells because of their relative ease of
isolation and because they represent the macrovascular
component while HMEC represent the microvascular compo-
nent of a tumor.36 Endothelial progenitor cells are found in the
bone marrow or within the pre-existing vasculature and they
represent more immature endothelial cells than HUVEC and
HMEC, participating in neovascularization including vasculo-
genesis and angiogenesis.37 These three cell types are models
of endothelial tumor cells and were used to distinguish them
from normal retinal or choroidal vasculature. Thus, we could
support a possible pharmacological effect as opposed to the
toxicity profile against the normal ocular tissue. In addition,
Mesri et al.38 described that the molecular phenotype of the
endothelium of vessels in tumors differed from endothelial
cells isolated from matched adjacent normal human tissue.
Specifically, they showed an upregulation of ATP1B3, the beta
subunit of the Naþ/Kþ ATPase. Taking into account that this
ATPase enzyme is the site of action of digoxin, further studies
are needed to assess the effect of its overexpression in tumor
endothelial cells and its relevance in the pharmacological
effect of digoxin. Based on the IC50 obtained after 72 hours of
digoxin exposure, the most sensitive cell type was the HUVEC.
Although small differences were encountered among the three
types, all showed an IC50 of approximately 20 nM. In addition,
we showed that apoptosis was the mechanism of digoxin-
induced death in endothelial cells. Previous reports by others
showed an IC50 of approximately 210 nM after treating
HUVEC cells with digoxin at a range of concentrations for
different times.15,39 In those studies the IC50 was calculated
after exposing the cells to digoxin for 48 hours, however, we
exposed cells to digoxin for 72 hours under the conventional
schedule. In addition, those reports showed that the cytotoxic
effect was concentration- and time-dependent. Thus, the
differences in the HUVEC IC50s between previous reports
and ours may be mainly due to the time-effect of digoxin on
cell growth.32 Altogether, this is the first study demonstrating
the effect of digoxin on EPC and HMEC endothelial cell types.
Finally, the results obtained from in vitro studies may differ
from in vivo results due to the interactions with vascular mural
cells, neurons, and glial cells needed for normal retinal
endothelial cell function. Thus, further studies are necessary
to confirm our results in vivo.
After a single intravitreal 10-lg dose of digoxin administered
to rabbits, we observed a favorable disposition of the drug with
high and sustained vitreous exposure and low plasma
concentrations. Considering the vitreous volume of the rabbit,
a maximum vitreous concentration (Cmax, vit) between 6.7 and
8.3 lg/mL was expected to be attained shortly after intravitreal
delivery.27 In agreement with this, our model predicted a
Cmax, vit of 8.5 lg/mL 5 minutes after injection. Based on the
IC50 obtained in the present study, an active pharmacological
concentration may be expected for 24 hours after intravitreous
administration (Fig. 4A). Interestingly, plasma digoxin levels
were below the lower limit of the therapeutic window13 at all
times after injection of a single dose. The large volume of
distribution of digoxin is due to the high affinity for skeletal
and cardiac muscles and the kidney. However, we observed no
measurable concentrations of digoxin in the kidneys or hearts
of our animal model. We observed a striking plasma-to-vitreous
exposure ratio that showed systemic digoxin exposure to be
only 0.04% of the amount in the vitreous compartment.
Therefore, after a 10-lg dose we observed a low plasma
bioavailability of digoxin and thus, this dose was not expected
to lead to systemic or cardiovascular toxicity. However, this
single dose was toxic to the retina of the rabbits, and thus
could not be translated to a potential human use unless a
modification to the scheme of treatment was introduced.
After four biweekly intravitreal injections in rabbits, we
registered no vascular retinal changes or systemic toxicity.
Nevertheless, we did observe local injury only at defined areas
TABLE 3. Electroretinography Response After Intravitreal Digoxin
Eye Treatment Group
Digoxin-
Treated
Vehicle-
Treated
b-wave
Amplitude
Baseline 159.5 (7.4) 139.5 (9.1)
After first dose 118.9 (22.0) 152.1 (3.7)
After second dose 66.3 (10.4)* 120.6 (53.4)
After third dose 56.3 (13.8)*† 173.7 (12.9)
After fourth dose 28.8 (12.5)*† 175.2 (26.8)
Implicit time
Baseline 33.9 (1.7) 33.8 (1.4)
After first dose 32.4 (1.4) 33.2 (1.6)
After second dose 32.5 (2.9) 30.1 (1.7)
After third dose 33.7 (2.0) 33.2 (2.2)
After fourth dose 25.6 (8.6) 34.0 (0.8)
a-wave
Amplitude
Baseline 88.4 (4.3) 61.6 (10.1)
After first dose 79.8 (13.4) 88.5 (10.4)
After second dose 59.4 (9.0) 54.8 (15.1)
After third dose 47.6 (6.3)*† 73.3 (6.2)
After fourth dose 14.4 (5.2)*† 69.9 (1.9)
Implicit time
Baseline 12.9 (0.4) 11.8 (0.7)
After first dose 13.9 (0.4) 13.1 (0.5)
After second dose 13.3 (0.1) 12.7 (0.5)
After third dose 13.0 (0.6) 11.9 (0.3)
After fourth dose 11.0 (3.8) 12.1 (0.3)
Electroretinographic amplitude and implicit time recordings in
rabbits after four biweekly injections of 1 lg digoxin or diluted vehicle.
Data is shown as mean (SD).
* P < 0.05 with respect to baseline (before digoxin injections).
† To the left eyes at the same time post treatment.
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FIGURE 6. Representative micrographs of the retinal sections and optic disks 2 weeks after the fourth dose of intravitreal digoxin (hematoxylin and
eosin stain, [A–H] original magnifications3125, and [I, J]325). Left column: vehicle-injected eye (control) and right column: digoxin-injected eye
of the same rabbit. The vehicle-treated eye showed a normal appearance of the peripheral (A), equatorial (C), and posterior (E) retina and
medullated nerve fibers (G). The digoxin-treated eye of the same rabbit showed marked atrophy of the outer retinal layer in the equatorial area (D)
while the peripheral (B), posterior (F), and medullated nerve fibers (H) were not affected. The optic disc and surface blood vessels (I, J) were
normal in the control and digoxin-injected eyes.
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that involved the outer retina (Fig. 6D) in the digoxin-treated
but not in the vehicle-injected eyes. Hence, the retinal damage
was not associated with vascular toxicity and necrosis.
Furthermore, the ERGs of the digoxin-treated eyes showed a
significant decrease in the a-wave and b-wave amplitude before
the third dose compared with the pretreatment state (P <
0.05). This reduction in both amplitudes may be the result of
the injected volume or a toxic effect of the injected vehicle;
however, the ERGs remained unchanged in vehicle-treated eyes
during the study period and the a- and b-wave amplitude
declined significantly in the digoxin-treated eyes compared
with the vehicle-treated eyes (P < 0.05) after three doses with
no recovery. Interestingly, we found no significant changes in a-
and b-wave implicit times in digoxin-treated eyes at a 1-lg
dose. The vehicle-treated eyes showed normal ERGs and
histopathology confirming that the elevation of IOP from
increased intraocular volume after injection was not the cause
of this finding. Altogether, these results suggest that the
observed toxicity implicates digoxin as the toxic agent.
One way to circumvent high exposures for short periods of
time but still attaining the same drug exposure is to increase
the frequency of drug administration but using lower doses or
a sustained-release formulation. This approach may yield the
same exposure-related pharmacological activity, associated
with lower toxicity, as it avoids tissue exposure to high local
drug concentrations that may be cytotoxic to both normal and
tumor cells. Conversely, conventional chemotherapy (using the
maximum-tolerated dose) targets rapidly dividing tumor cells,
but also cells from normal tissues, triggering a series of adverse
and sometimes life-threatening events. Therefore, in this study
we examined the value of metronomic treatment with digoxin
in endothelial and retinoblastoma cell types. We observed no
difference in the calculated IC50 of the three endothelial cell
types comparing the conventional with the continuous
treatment (P > 0.05). Similarly, we did not observe a decrease
in the IC50 of retinoblastoma cell lines when comparing both
treatment schedules. Altogether, continuous exposure to
digoxin may not be a better treatment option as it does not
allow a dose reduction compared with conventional treatment
for retinoblastoma control and antiangiogenic effect.
In conclusion, the present study showed that digoxin exerts
a strong antiangiogenic effect and cytotoxicity against retino-
blastoma in vitro and that the antiproliferative effects of
digoxin were mediated mostly by apoptosis inducing cell-cycle
arrest at G0. Digoxin showed favorable vitreous pharmacoki-
netics attaining pharmacologically active concentrations for up
to 24 hours after a single intravitreal injection in the rabbit eye
while plasma concentrations were far below the concentration
that triggers cardiac toxicity in humans. Therefore, based on
our results, intravitreal digoxin may be considered for further
clinical study in retinoblastoma patients with relapsed vitreous
seeds.
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